{"nctId":"NCT00972738","briefTitle":"Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)","startDateStruct":{"date":"2001-04"},"conditions":["Seasonal Allergic Rhinitis"],"count":1214,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: montelukast sodium"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: loratadine"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"montelukast sodium","otherNames":[]},{"name":"Comparator: loratadine","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has a documented history of season allergic rhinitis symptoms that flare up during the study season\n* Patient is a nonsmoker\n* Patient is in good general health\n\nExclusion Criteria:\n\n* Patient is hospitalized\n* Patient is a woman who is \\<8 weeks postpartum or is breast-feeding\n* Patient has had major surgery in the past 4 weeks\n* Patient intends to move or vacation away during the study\n* Patient is a current or past abuser of alcohol or illicit drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"85 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period","description":"Mean change from baseline in Daytime Nasal Symptoms. Patients were asked to rate each of the 4 nasal symptoms of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4-point scale \\[Score 0 (best) to 3 (worst)\\]. The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal Symptoms Score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":null},{"groupId":"OG001","value":"-0.47","spread":null},{"groupId":"OG002","value":"-0.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Nighttime Symptoms Score Over the 2-week Treatment Period","description":"Mean change from baseline in Nighttime Symptoms Score. Patients were asked to rate each symptoms of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings daily on a 4-point \\[Scale 0 (best) to 3 (worst)\\]. The average of the individual symptoms scores was reported as the Nighttime Symptoms Score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":null},{"groupId":"OG001","value":"-0.28","spread":null},{"groupId":"OG002","value":"-0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Daytime Eye Symptoms Score Over the 2-week Treatment Period","description":"Mean change from baseline in Daytime Eye Symptoms scores. Patients were asked to rate each of the 4 eye symptoms of tearing, itchy, red, and puffy eyes daily on a 4-point scale \\[0 (best) to 3 (worst)\\]. The average of the 4 individual eye symptoms scores was reported as the Daytime Eye Symptoms Score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":null},{"groupId":"OG001","value":"-0.40","spread":null},{"groupId":"OG002","value":"-0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period","description":"An evaluation by the patient, administered at the last visit (or upon discontinuation) using a 7-point scale \\[Score 0 (very much better) to 6 (very much worse)\\], of the change in symptoms as compared to the beginning of the study.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":null},{"groupId":"OG001","value":"2.19","spread":null},{"groupId":"OG002","value":"2.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period","description":"An evaluation by the physician, administered at the last visit (or upon discontinuation) using a 7-point scale \\[Score 0 (very much better) to 6 (very much worse)\\], of the change in symptoms as compared to the beginning of the study.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":null},{"groupId":"OG001","value":"2.16","spread":null},{"groupId":"OG002","value":"2.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Rhinoconjunctivitis Quality-of-Life Score After the 2-week Treatment Period","description":"Patients completed a validated, self-administered Rhinoconjunctivitis Quality-of-Life Questionnaire, which included 28 questions on a 7-point scale \\[Score 0 (best) to 6 (worst)\\], across 7 domains: activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional. The individual domain scores were calculated as the average values of all scores within a domain, then the scores for the 7 domains were averaged for the overall score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":null},{"groupId":"OG001","value":"-0.98","spread":null},{"groupId":"OG002","value":"-0.66","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":522},"commonTop":[]}}}